EpiCept this week announced that Gert Caspritz has resigned from the company's board of directors, effective March 6.
Caspritz, a general partner of TVM Capital, has been a member of the board since 1999 and served as EpiCept's chairman from July 2002 until December 2004.
Znomics has named Stephane Berghmans as director of drug discovery, effective March 10, the company announced this week.
Berghmans was most recently head of safety pharmacology at Summit.